Results 111 to 120 of about 2,175,372 (155)

A lenvatinib-resistance-derived transcriptional program identifies metabolic identity remodeling associated with unfavorable survival in hepatocellular carcinoma

Background: Metabolic adaptation is a recognized feature of therapeutic resistance in hepatocellular carcinoma (HCC), but it is unclear whether transcriptional states exposed during acquired resistance are restricted to drug adaptation or reflect broader
Li Zheng, Lu Gan
core   +1 more source

Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma. [PDF]

Cancer Res
Sun Y, Luo C, Yang H, Ye J, Song F, Yi Q, Zou W, Huang Y, Fan X, Wang L, Zhang Y, Ding Q, Zhu Y, Tang Z.   +13 more
europepmc   +1 more source

Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma

Background/Aims: At present, there are relatively few reports on the treatment consisting of transarterial chemoembolization (TACE) combined with lenvatinib, and there is no unified conclusion on the curative effect. The objective of this research was to
Daixin Li, Xinmiao Xiong, Wei Ye, Rongyu Tang, Chenqi Xue, Mingyu Li, Zheng Zong, Jing Fan   +7 more
core   +1 more source

COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling". [PDF]

Clin Mol Hepatol
Han JW.
europepmc   +1 more source

p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling. [PDF]

Mol Cell Biochem
Cheng N, Liu K, Qi X, Cai L, Zhou Y, Wang F, Zhao B, Wang Y.   +7 more
europepmc   +1 more source

Androgen receptor drives lenvatinib resistance in hepatocellular carcinoma through transcriptional activation of EIF3I and a downstream ceRNA axis. [PDF]

Oncol Lett
Liu C, Zhang B, Jin Y, Chen Z, Wang M, Wu Z.   +5 more
europepmc   +1 more source

Sintilimab Plus Lenvatinib with or Without Radiotherapy for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis [PDF]

Chang Liu,1,2,* Weixing Jiang,3,* Juxian Sun,1,* Jingwei Cui,4 Dandan He,1 Shuqun Cheng,1 Jie Shi1 1Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, People’s Republic ...
Cheng S, He D, Jiang W, Cui J, Liu C, Shi J, Sun J   +6 more
core  

Calcium peroxide loaded liposomes reprogram hypoxic and acidic tumor microenvironment to overcome lenvatinib resistance in hepatocellular carcinoma. [PDF]

Mater Today Bio
Bai Y, Li X, Lei Y, Yao W, Bai X, Su Y, Lu Y, Zheng C, Kan X, Wang Y.   +9 more
europepmc   +1 more source

The KRT15 and KRT81 complex promotes lenvatinib resistance in thyroid cancer by upregulating DGKB mediated lipid metabolism. [PDF]

Sci Rep
Wang Y, Zhang Y, Zhao D, Wu Y, Liao T, Wang Y, Xiang J, Chen Q, Sun T.   +8 more
europepmc   +1 more source

Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade.
石, 婷婷, シ, ティエンティエン, Shi, Tingting   +2 more
core